Risperidone in Children with Autism and Serious Behavioral Problems
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Atypical antipsychotic agents, which block postsynaptic dopamine and serotonin receptors, have advantages over traditional antipsychotic medications in the treatment of adults with schizophrenia and may be beneficial in children with autistic disorder who have serious behavioral disturbances. However, data on the safety and efficacy of atypical antipsychotic agents in children are limited. METHODS: We conducted a multisite, randomized, double-blind trial of risperidone as compared with placebo for the treatment of autistic disorder accompanied by severe tantrums, aggression, or self-injurious behavior in children 5 to 17 years old. The primary outcome measures were the score on the Irritability subscale of the Aberrant Behavior Checklist and the rating on the Clinical Global Impressions - Improvement (CGI-I) scale at eight weeks. RESULTS: A total of 101 children (82 boys and 19 girls; mean [+/-SD] age, 8.8+/-2.7 years) were randomly assigned to receive risperidone (49 children) or placebo (52). Treatment with risperidone for eight weeks (dose range, 0.5 to 3.5 mg per day) resulted in a 56.9 percent reduction in the Irritability score, as compared with a 14.1 percent decrease in the placebo group (P<0.001). The rate of a positive response, defined as at least a 25 percent decrease in the Irritability score and a rating of much improved or very much improved on the CGI-I scale, was 69 percent in the risperidone group (34 of 49 children had a positive response) and 12 percent in the placebo group (6 of 52, P<0.001). Risperidone therapy was associated with an average weight gain of 2.7+/-2.9 kg, as compared with 0.8+/-2.2 kg with placebo (P<0.001). Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison). In two thirds of the children with a positive response to risperidone at eight weeks (23 of 34), the benefit was maintained at six months. CONCLUSIONS: Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder. The short period of this trial limits inferences about adverse effects such as tardive dyskinesia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Methylphenidate, atomoxetine and guanfacine are beneficial for ADHD symptoms in ASD (Table 2 204 -206 )”
From Autism spectrum disorder (2020) · cites this paper as [206]
In the citing paper
“Currently, only two drugs have been approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the ASD population: risperidone [23] and aripiprazole [24]. Both drugs are approved for the treatment of irritability in children and adolescents with ASD.”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“as the two drugs that have received FDA approval for use in ASD, risperidone, and aripiprazole, are both for the indication of “irritability” [23, 24]”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“risperidone and aripiprazole, which are both FDA-approved for irritability in children and adolescents with ASD [23, 24].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“and significant improvement in core autism symptoms [601-604].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [601]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Littell, R. C. (1996) · Medical Entomology and Zoology · Cited by 10,547
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Pervasive Developmental Disorders in preschool children
Chakrabarti, S. (2001) · JAMA · doi:10.1001/jama.285.24.3093 · Cited by 1,132
Gibbons, R. D. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820210073009 · Cited by 719
McDougle, C. J., Holmes, J. P., Carlson, D. C., Pelton, G. H., Cohen, D. J., & Price, L. H. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.633 · Cited by 427
Self-citationDiagnosing Autism: Analyses of Data from the Autism Diagnostic Interview
Lord, C., Pickles, A., McLennan, J., Rutter, M., Bregman, J., Folstein, S., Fombonne, E., Leboyer, M., & Minshew, N. (1997) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1025873925661 · Cited by 373
The Vineland Adaptive Behavior Scales: Supplementary Norms for Individuals with Autism
Carter, A. S., Volkmar, F. R., Sparrow, S. S., Wang, J.-J., Lord, C., Dawson, G., Fombonne, E., Loveland, K., Mesibov, G., & Schopler, E. (1998) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1026056518470 · Cited by 367
Self-citation
Cited by
Items 701–800 of 1,000
Pharmacogenomics of Autism Spectrum Disorder
Brown, J. T., Eum, S., Cook, E. H., & Bishop, J. R. (2017) · Pharmacogenomics · doi:10.2217/pgs-2016-0167 · Cited by 25
Coughlin, M., Goldie, C., Tranmer, J. E., Khalid‐Khan, S., & Tregunno, D. (2018) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717751693 · Cited by 28
Ruisch, I. H., Dietrich, A., Klein, M., Faraone, S. V., Oosterlaan, J., Buitelaar, J. K., & Hoekstra, P. J. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0608-0 · Cited by 24
Wang, L., Peng, J., Qiao, F., Cheng, W.-M., Lin, G.-W., Zhang, Y., Gao, T.-G., Sun, Y., Tang, W., & Wang, P. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/5549849 · Cited by 23
“In addition, long-term drug use results in side effects, such as weight gain, fatigue, drowsiness, and tremors, for example, risperidone treatment [13, 14].”
BackgroundAutism: a target of pharmacotherapies?
Gerlai, R. T., & Gerlai, J. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03039-9 · Cited by 27
Boon‐yasidhi, V., Jearnarongrit, P., Tulayapichitchock, P., & Tarugsa, J. (2014) · Psychiatry Journal · doi:10.1155/2014/136158 · Cited by 29
Pharmacologic Treatment of Autism and Related Disorders
Erickson, C. A., Posey, D. J., Stigler, K. A., & McDougle, C. J. (2007) · Pediatric Annals · doi:10.3928/0090-4481-20070901-09 · Cited by 24
Self-citationFarmer, C., & Aman, M. G. (2021) · Springer eBooks · doi:10.1007/978-3-319-91280-6_1632 · Cited by 24
Self-citationRisperidone reduction of amphetamine-induced self-injurious behavior in mice
Wagner, G. C., Avena, N., Kita, T., Nakashima, T., Fisher, H., & Halladay, A. K. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.11.009 · Cited by 22
Pharmacogenomic Medicine in Autism: Challenges and Opportunities
Bowers, K., Lin, P.-I., & Erickson, C. (2015) · Pediatric Drugs · doi:10.1007/s40272-014-0106-0 · Cited by 22
Spanos, M., Chandrasekhar, T., Kim, S., Hamer, R. M., King, B. H., McDougle, C. J., Sanders, K. B., Gregory, S. G., Kolevzon, A., Veenstra-VanderWeele, J. M., et al. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106103 · Cited by 23
Self-citationAlrehaili, R. A., Elkady, R. M., Alrehaili, J. A., & Alreefi, R. (2023) · Cureus · doi:10.7759/cureus.50111 · Cited by 33
“Risperidone and aripiprazole have received FDA approval for addressing irritability associated with ASD, with risperidone approved for children aged at least five years and aripiprazole for those at least six years old [56].”
BackgroundTherapeutic approaches for shankopathies
Wang, X., Bey, A. L., Chung, L., Krystal, A. D., & Jiang, Y. (2013) · Developmental Neurobiology · doi:10.1002/dneu.22084 · Cited by 27
“Two medications, risperidone and aripiprazole, have been approved by the Food and Drug Administration (FDA) to treat the comorbidities commonly seen in ASD (McCracken et al., 2002; Marcus et al., 2011a,b; McPheeters et al. 2011).”
BackgroundNovel uses for risperidone: focus on depressive, anxiety and behavioral disorders
Ravindran, A. V., Bradbury, C. L., McKay, M. S., & da Silva, T. L. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.11.1693 · Cited by 24
“, (2002) [112] 8-week, double-blind, placebo-controlled study n = 101 DSM-IV – AD Age 5 – 17 years ABC CGI RIS (n = 49; 0.”
BackgroundAssessment and Treatment in Autism Spectrum Disorders: A Focus on Genetics and Psychiatry
Butler, M. G., Youngs, E. L., Roberts, J., & Hellings, J. A. (2012) · Autism Research and Treatment · doi:10.1155/2012/242537 · Cited by 25
Increases in Identified Cases of Autism Spectrum Disorders
Steuernagel, T. (2005) · Journal of Disability Policy Studies · doi:10.1177/10442073050160030101 · Cited by 22
“Despite the vilification of the pharmaceutical companies by many in the autism community, there is evidence that some drugs, although not a cure for autism, are useful in the treatment of autistic symptoms, including aggression and obsessive–compulsive behaviors (Aman, Lam, & Collier-Crespin, 2003; McCracken et al., 2…”
BackgroundRomán, V., Adham, N., Foley, A., Hanratty, L., Farkas, B., Lendvai, B., & Kiss, B. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05851-6 · Cited by 25
N -Acetylcysteine as Treatment for Self-Injurious Behavior in a Child with Autism
Marler, S., Sanders, K. B., & Veenstra-VanderWeele, J. M. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2013.0137 · Cited by 24
“…the treatment of irritability, and compulsive and disruptive behaviors has been demonstrated in large-scale, randomized controlled trials (RCTs), little evidence exists for specific benefit for SIB (McCracken et al. 2002; Shea et al. 2004; McDougle et al. 2005; Marcus et al. 2009; Owen et al. 2009).”
Drug-induced movement disorders in children and adolescents
Rodnitzky, R. L. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.1.91 · Cited by 23
“Laryngospasm with compromise of the airway is a rare, but potentially fatal, form of ADR [6].”
ResultInfluentialMcDougle, C. J., Stigler, K. A., Erickson, C. A., & Posey, D. J. (2006) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2006.06.012 · Cited by 26
Self-citationScahill, L. D., & Martin, A. (2005) · Wiley eBooks · doi:10.1002/9780470939352.ch18 · Cited by 23
Self-citationUtilisation des antipsychotiques chez l’enfant et l’adolescent
Bonnot, O., & Holzer, L. (2011) · Neuropsychiatrie de l Enfance et de l Adolescence · doi:10.1016/j.neurenf.2011.07.003 · Cited by 21
Rezaei, M., Moradi, A., Tehrani‐Doost, M., Hassanabadi, H., & Khosroabadi, R. (2018) · Children · doi:10.3390/children5020019 · Cited by 23
“Risperidone is an antipsychotic and post-synaptic blocker of serotonin and dopamine receptors, and its short-term effect on severe behavioral problems in children with autism has been confirmed in several studies; the most noticeable effects of this drug seem to be in the areas of hyperactivity, aggression and repetit…”
BackgroundKouhbanani, S. S., Khosrorad, R., Zarenezhad, S., & Arabi, S. M. (2021) · Archives of Iranian Medicine · doi:10.34172/aim.2021.76 · Cited by 24
Smith, E., Stogios, N., Au, E., Maksyutynska, K., De, R., Ji, A., Sørensen, M. E., John, L. S., Lin, H., Desarkar, P., et al. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13484 · Cited by 23
“Six low quality studies were identified.(22,24,26,27,30,34,36) When removed, weight gain was still significantly greater with AP use compared with placebo when reported as a continuous (MD = 0.”
Backgroundde Hoogd, S., Overbeek, W. A., Heerdink, E. R., Correll, C. U., de Graeff, E. R., & Staal, W. (2012) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2011.0079 · Cited by 25
An Open-label Trial of Risperidone and Fluoxetine in Children with Autistic Disorder
Desousa, A. (2010) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.70522 · Cited by 22
“[33] Risperidone has been known to reduce anger, hyperactivity and aggression in autism, mental retardation, conduct disorder, oppositional defiant disorder, childhood-onset schizophrenia and attention deficit hyperactivity disorder (ADHD).”
Clozapine for Drug-Refractory Irritability in Individuals with Developmental Disability
Wink, L. K., Badran, I., Pedapati, E. V., Sorensen, R., Benton, S. C., Johnson, M. C., Wissel, G., & Erickson, C. A. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0216 · Cited by 22
Drug treatment of autism spectrum disorder and its comorbidities in children and adolescents
Santosh, P., & Singh, J. (2016) · BJPsych Advances · doi:10.1192/apt.bp.115.014597 · Cited by 24
“It has been reported that risperidone is effective in targeting self-injurious behaviour, especially in severe cases (McCracken 2002).”
InfluentialBrief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder
Wink, L. K., Adams, R. E., Pedapati, E. V., Dominick, K. C., Fox, E., Buck, C., & Erickson, C. A. (2017) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-017-3132-2 · Cited by 21
Sahoo, S., Padhy, S. K., Singla, N., & Singh, A. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.07.012 · Cited by 21
Aggressive behavior in transgenic animal models: A systematic review
Jager, A., Maas, D. A., Fricke, K., de Vries, R. B., Poelmans, G., & Glennon, J. C. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.09.028 · Cited by 22
“mood disorders, depressive disorder and anxiety disorders that often have co-morbid aggression or dysregulation of emotional processing (Kohn et al., 2009; McCracken et al., 2002; Taylor et al., 1996).”
Banas, K., & Sawchuk, B. (2020) · PubMed · Cited by 24
Impact of Recent Findings on Study Design of Future Autism Clinical Trials
Hollander, E., Phillips, A., King, B. H., Guthrie, D., Aman, M. G., Law, P. A., Owley, T. B., & Robinson, R. (2004) · CNS Spectrums · doi:10.1017/s109285290000835x · Cited by 21
Self-citationDinnissen, M., Dietrich, A., van den Hoofdakker, B. J., & Hoekstra, P. J. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.981151 · Cited by 25
“Pivotal trials NCT00080145 [42] NCT00261508 [45] M.”
InfluentialWeeden, M., Ehrhardt, K. E., & Poling, A. D. (2009) · Research in Autism · doi:10.1016/j.rasd.2009.06.004 · Cited by 23
“A number of other published studies also demonstrated generally beneficial effects and it now appears that risperidone is reasonably effective in reducing challenging behavior in children with autism (e.g., Miral et al., 2008; McCracken et al., 2002; Shea et al., 2004).”
ResultRisperidone and olanzapine in adults with intellectual disability: a clinical naturalistic study
Bokszanska, A., Martin, G., Vanstraelen, M., Holt, G., Bouras, N., & Taylor, D. M. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200309000-00005 · Cited by 25
“noted in sociability, hyperactivity, labile affect, tantrums, aggressive outbursts and self-injurious behaviour (Horrigan and Barnhill, 1997; Masi et al., 2001; McCracken et al., 2002).”
BackgroundSchwartzer, J. J., Morrison, R. L., Ricci, L. A., & Melloni, R. H. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1412-4 · Cited by 21
Antipsychotic drugs in children with autism
Morgan, S. N., & Taylor, E. A. (2007) · BMJ · doi:10.1136/bmj.39216.583333.80 · Cited by 23
“Two well conducted double blind placebo controlled studies have compared placebo and the atypical antipsychotic risperidone in children with autism and behavioural problems. One study”
BackgroundPsychotropic medications in autism: practical considerations for parents
Williamson, E. D., & Martin, A. (2012) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-010-1144-2 · Cited by 20
Self-citationBehavioral Management of Children With Autism in the Emergency Department
Wolpert, K. H., Kodish, I. M., Kim, S., & Uspal, N. G. (2022) · Pediatric Emergency Care · doi:10.1097/pec.0000000000002886 · Cited by 20
What’s in the pipeline? Drugs in development for autism spectrum disorder
Sung, M., Chin, C. H., Lim, C. G., Liew, A., Lim, C. S., Kashala-Abotnes, E., & Weng, S. J. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s39516 · Cited by 26
Özşahin, İ., Mustapha, M. T., Albarwary, S. A., Şanlıdağ, B., Ozsahin, D. U., & Butler, T. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0162 · Cited by 22
Miyaoka, T., Wake, R., Furuya, M., Liaury, K., Ieda, M., Kawakami, K., Tsuchie, K., Inagaki, T., & Horiguchi, J. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-215 · Cited by 22
Ricci, L. A., Connor, D. F., Morrison, R. L., & Melloni, R. H. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.052 · Cited by 20
Prescribing practices of community child and adolescent psychiatrists
Doerry, U., & Kent, L. (2003) · Psychiatric Bulletin · doi:10.1192/pb.27.11.407 · Cited by 20
“…less of an issue with atypical antipsychotic medication and there is recent evidence from double-blind placebo-controlled trials that risperidone is effective in the treatment of aggressive behaviour in children and adolescents (Findling et al, 2000; Aman et al, 2002; McCracken et al, 2002).”
BackgroundPediatric and Adolescent Psychopharmacology: A Practical Manual for Pediatricians
Greydanus, D. E., Calles, J. L., & Patel, D. R. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544705 · Cited by 20
The effect of music interventions in autism spectrum disorder: a systematic review and meta-analysis
Navarro, L., Mallah, N. E. Z., Nowak, W., Pardo-Seco, J., Gómez‐Carballa, A., Pischedda, S., Martinón‐Torres, F., & Salas, A. (2025) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2025.1673618 · Cited by 21
Tiwari, A., Rahi, S., & Mehan, S. (2020) · Current Drug Targets · doi:10.2174/1389450121666201020155010 · Cited by 19
Co-morbidity and patterns of care in stimulant-treated children with ADHD in the Netherlands
Faber, A., Kalverdijk, L. J., den Berg, L. T. W. D. J., Hugtenburg, J. G., Minderaa, R. B., & Tobi, H. (2009) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0075-y · Cited by 21
Complementary and Alternative Treatments for Autism Part 1: Evidence-Supported Treatments
Bent, S., & Hendren, R. L. (2015) · The AMA Journal of Ethic · doi:10.1001/journalofethics.2015.17.4.sect1-1504 · Cited by 19
Li, A., & Poling, A. D. (2018) · Behavior Analysis in Practice · doi:10.1007/s40617-018-0237-9 · Cited by 21
“This is, for example, true with respect to the effects of risperidone on irritability (e.g., Elbe & Lalani, 2012; McCracken et al., 2002).”
BackgroundSingh, N. N., Lancioni, G. E., Myers, R. E., Karazsia, B. T., McPherson, C. L., Jackman, M. M., Kim, E.-J., & Thompson, T. M. (2018) · Advances in Neurodevelopmental Disorders · doi:10.1007/s41252-018-0073-5 · Cited by 21
Psychopharmacologic treatment of aggressive preschoolers: A chart review
Staller, J. A. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.08.009 · Cited by 19
“In a recent double blind placebo controlled study of 101 autistic children, risperidone was found to be effective and safe in ameliorating aggressive symptoms (McCracken et al., 2002).”
BackgroundSuccessful risperidone treatment for behavioral disturbances in Prader–Willi syndrome
Araki, S., Ohji, T., Shiota, N., Dobashi, K., Shimono, M., & Shirahata, A. (2010) · Pediatrics International · doi:10.1111/j.1442-200x.2009.02996.x · Cited by 19
Farmer, C., Lecavalier, L., Yu, S., Arnold, L. E., McDougle, C. J., Scahill, L. D., Handen, B. L., Johnson, C. R., Stigler, K. A., Bearss, K. E., et al. (2011) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-011-1338-2 · Cited by 25
Self-citationAutism Spectrum Disorder: An Update
Azeem, M. W., Imran, N., & Khawaja, I. S. (2016) · Psychiatric Annals · doi:10.3928/00485713-20151202-01 · Cited by 23
Risperidone-Induced Obsessive-Compulsive Symptoms in Two Children
Diler, R. S., Tahiroğlu, A. Y., Avcı, A., & Scahill, L. D. (2003) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454603322126386 · Cited by 19
“Several recent studies have also demonstrated that risperidone is superior to placebo in reducing irritable, aggressive, and impulsive behavior in children with autism and other developmental disabilities (Aman et al. 2002; McCracken et al. 2002; Tur-gay et al. 2002).”
Self-citationAutism Spectrum Disorders: An Overview
Goldson, E. (2004) · Advances in Pediatrics · doi:10.1016/s0065-3101(23)00036-1 · Cited by 19
Murphy, D., Glaser, K., Hayward, H., Eklund, H., Cadman, T., Findon, J., Woodhouse, E., Ashwood, K., Beecham, J., Bolton, P., et al. (2018) · Programme Grants for Applied Research · doi:10.3310/pgfar06020 · Cited by 18
Autism Spectrum Disorder and Epilepsy: Pathogenetic Mechanisms and Therapeutic Implications
Giliberti, A., Frisina, A. M., Giustiniano, S., Carbonaro, Y., Roccella, M., & Nardello, R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14072431 · Cited by 26
“[62,80,180, 273– 300 ] The pharmacological management of pediatric patients with ASD and comorbid epilepsy presents a multifaceted challenge.”
Gürkan, R. K., & Koçak, F. (2021) · International Journal of Developmental Disabilities · doi:10.1080/20473869.2021.2009636 · Cited by 20
“Using psychological/pharmacological medications were observed to have a reduction in temper tantrums and aggressive attack numbers; however, side effects like increased appetite, dizziness, increased salivation, lethargy and fatigue were observed individuals (McCracken et al. 2002).”
BackgroundYan, H., Siegel, L., Breitbart, S. C., Gorodetsky, C., Fasano, A. A., Rahim, A., Loh, A., Kulkarni, A. V., & Ibrahim, G. M. (2022) · Pilot and Feasibility Studies · doi:10.1186/s40814-022-00988-3 · Cited by 22
Aspectos genéticos y neuroendocrinos en el trastorno del espectro autista
Oviedo, N., Apolinar, L. M., de la Chesnaye, E., & Guerra‐Araiza, C. (2015) · Boletín Médico del Hospital Infantil de México · doi:10.1016/j.bmhimx.2015.01.010 · Cited by 56
Endosomal system genetics and autism spectrum disorders: A literature review
Patak, J., Zhang‐James, Y., & Faraone, S. V. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.03.022 · Cited by 23
Wink, L. K., Pedapati, E. V., Adams, R. E., Erickson, C. A., Pedersen, K. A., Morrow, E. M., Kaplan, D., & Siegel, M. S. (2017) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-017-3153-x · Cited by 19
Lurasidone for the treatment of irritability and anger in autism spectrum disorders
McClellan, L., Dominick, K. C., Pedapati, E. V., Wink, L. K., & Erickson, C. A. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1353600 · Cited by 21
Weeden, M., Ehrhardt, K. E., & Poling, A. D. (2010) · Behavior Analysis in Practice · doi:10.1007/bf03391753 · Cited by 22
Self‐injurious behaviour: limbic dysregulation and stress effects in an animal model
Muehlmann, A. M., Kies, S. D., Turner, C. A., Wolfman, S. L., Lewis, M. H., & Devine, D. P. (2011) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2011.01485.x · Cited by 20
Handen, B. L., Johnson, C. R., Butter, E. M., Lecavalier, L., Scahill, L. D., Aman, M. G., McDougle, C. J., Arnold, L. E., Swiezy, N. B., Sukhodolsky, D. G., et al. (2012) · Journal of Developmental and Physical Disabilities · doi:10.1007/s10882-012-9316-y · Cited by 21
Self-citationAutism Spectrum Disorders in Iran
Mohammadi, M., Salmanian, M., & Akhondzadeh, S. (2011) · InTech eBooks · doi:10.5772/38965 · Cited by 11
Update on psychopharmacology for autism spectrum disorders
Bertelli, M. O., Rossi, M., Keller, R., & Lassi, S. (2016) · Advances in Mental Health and Intellectual Disabilities · doi:10.1108/amhid-10-2015-0049 · Cited by 20
Asperger's Disorder and Co-Morbid Bipolar Disorder: Diagnostic and Treatment Challenges
Gutkovich, Z. A., Carlson, G. A., Carlson, H. E., Coffey, B. J., & Wieland, N. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.1723 · Cited by 26
“…pervasive developmental disorders, are frequent and compelling enough to be the object of considerable pharmacologic research and treatment (e.g., McCracken et al. 2002; Hollander et al. 2006) with lithium carbonate, or combined lithium and neuroleptics, have been reported to be of help in…”
Dumortier, G., Welniarz, B., Sauvebois, C., Medjdoub, H., Friche, H., Siad, N., & Degrassat, K. (2005) · L Encéphale · doi:10.1016/s0013-7006(05)82409-1 · Cited by 22
Kaiser, A. P., & McIntyre, L. L. (2010) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-115-5.357 · Cited by 19
Deep brain stimulation for autism spectrum disorder
Marini, S., D’Agostino, L., Ciamarra, C., & Gentile, A. (2023) · World Journal of Psychiatry · doi:10.5498/wjp.v13.i5.174 · Cited by 18
Cannabidiol is a behavioral modulator in BTBR mouse model of idiopathic autism
Shrader, S. H., Mellen, N. M., Cai, J., Barnes, G. N., & Song, Z.-H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1359810 · Cited by 19
“These atypical (second generation) antipsychotics have been shown to mildly improve stereotypy and repetitive behaviors (McDougle et al., 1998; McCracken et al., 2002; Shea et al., 2004; Marcus et al., 2009; Owen et al., 2009).”
BackgroundConstantine, R. J., Tandon, R., McPherson, M., & Andel, R. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0068 · Cited by 17
“…the tendency to use risperidone was probably driven by the data published in the early 2000s, indicating that risperidone may be effective in the treatment of disruptive behavior disorder and of irritability and impulsivity of children with autism (McCracken et al. 2002; McClellan and Werry 2003).”
A Retrospective Study of Amitriptyline in Youth with Autism Spectrum Disorders
Bhatti, I., Thome, A. P., Smith, P. O., Cook‐Wiens, G., Yeh, H., Gaffney, G., & Hellings, J. A. (2012) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-012-1647-0 · Cited by 19
Mongillo, D. L., Kosyachkova, E. A., Nguyen, T. M., & Holmes, M. M. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.10.023 · Cited by 20
Self-injurious behavior: A comparison between Prader-Willi syndrome, Down syndrome and Autism
Buono, S., Scannella, F., & Palmigiano, M. B. (2010) · Cited by 17
Autism Spectrum Disorders: Etiology and Pharmacotherapy
Mohammadi, M.-R., & Akhondzadeh, S. (2007) · Current Drug Therapy · doi:10.2174/157488507780619095 · Cited by 18
“There were no improvements on objective measurements of social behavior and language, suggesting that the drug targets nonspecific behavioral problems associated with autism [49, 50].”
BackgroundThe use of antipsychotics in preschoolers: A veto or a sensible last option?
Memarzia, J., Tracy, D. K., & Giaroli, G. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113519506 · Cited by 17
Volkmar, F. R. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.42 · Cited by 17
Self-citationNeurologic treatment strategies in autism: An overview of medical intervention strategies
Chez, M. G., Memon, S. A., & Hung, P. C. (2004) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2004.07.007 · Cited by 19
Psychopharmacologic treatment of aggression in children and adolescents.
Ruths, S., & Steiner, H. (2004) · Pediatric annals · doi:10.3928/0090-4481-20040501-10 · Cited by 18
Friedman, N. D. B., Politte, L. C., Nowinski, L. A., & McDougle, C. J. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch44 · Cited by 17
Self-citationFarmer, C., & Aman, M. G. (2017) · Springer eBooks · doi:10.1007/978-1-4614-6435-8_1632-3 · Cited by 17
Self-citationde Bildt, A. A., Mulder, E. J., Scheers, T., Minderaa, R. B., & Tobi, H. (2006) · PEDIATRICS · doi:10.1542/peds.2005-3101 · Cited by 18
Ghaeli, P., Nikvarz, N., Alaghband‐Rad, J., Alimadadi, A., & Tehrani‐Doost, M. (2014) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.127254 · Cited by 19
“[4-6,19,23] For instance, in a study on 101 patients with autistic disorder, risperidone did not significantly decrease “stereotypy” subscale of ABC.”
InfluentialKlin, A., Wetherby, A. M., Woods, J. J., Saulnier, C. A., Stapel‐Wax, J. L., Klaiman, C., Jones, W., Rubin, E., Scahill, L. D., Call, N. A., et al. (2015) · Europe PMC (PubMed Central) · Cited by 22
Self-citationMcLaren, J., & Lichtenstein, J. D. (2018) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796018000604 · Cited by 19
“Clinical trials show psychotropic medications reduce challenging behaviours in childrenwith autism, but also cause increased rates of adverse events such as somnolence, upper respiratory infection, and increased appetite and weight gain (McCracken et al., 2002; Marcus et al., 2011).”
BackgroundValdovinos, M. G. (2019) · Current Developmental Disorders Reports · doi:10.1007/s40474-019-00179-5 · Cited by 20
Scheithauer, M. C., Call, N. A., Mevers, J. L., McCracken, C., & Scahill, L. D. (2020) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-020-04753-4 · Cited by 19
Self-citationBaker, M., Huefner, J. C., Bellonci, C., Hilt, R. J., & Carlson, G. A. (2021) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2020.0162 · Cited by 17
“The initial primary outcome measure, the Aberrant Behavior Checklist—Irritability scale, used to measure irritability with autism research (McCracken et al. 2002; Marcus et al. 2009), was found to be inappropriate for the study population.”
Ma, X., & Yang, J. (2021) · Mobile Information Systems · doi:10.1155/2021/6020208 · Cited by 18
Mutwalli, H., Keeler, J. L., Bektas, S., Dhopatkar, N., Treasure, J. L., & Himmerich, H. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.02.006 · Cited by 20
“…ratio of appetite increase versus no change in appetite between 392 participants on SGAs and 374 controls from eight studies (Aman et al., 2005; Black et al., 2014; Guardia et al., 2004; Litten et al., 2012; McCracken et al., 2002; Roerig et al., 2005; Snyder et al., 2002; Srivastava et al., 2012).”
BackgroundOnaolapo, O. J., & Onaolapo, A. Y. (2018) · AIMS Medical Science · doi:10.3934/medsci.2018.2.122 · Cited by 19
Physician collaboration involving students with Autism Spectrum Disorders
Ellis, C. R., Lutz, R. E., Schaefer, G. B., & Woods, K. E. (2007) · Psychology in the Schools · doi:10.1002/pits.20262 · Cited by 17
The role of medication in the management of behaviour problems in people with learning disabilities
Deb, S. S. (2007) · Advances in Mental Health and Learning Disabilities · doi:10.1108/17530180200700017 · Cited by 18
Metadata
- Authors
- McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., McDougle, C. J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., Lancor, A., Tierney, E., Ghuman, J., Gonzalez, N. M., Grados, M., Vitiello, B., Ritz, L., Davies, M., Robinson, J., & McMahon, D.
- Affiliations
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08
- Volume
- 347
- Issue
- 5
- Pages
- 314-321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1968430210
- Cited by
- 1,574
- References
- 25
- Citations by year
- 2026: 50 · 2025: 68 · 2024: 54 · 2023: 43 · 2022: 51 · 2021: 77 · 2020: 54 · 2019: 43 · 2018: 69 · 2017: 56 · 2016: 57 · 2015: 59 · 2014: 57 · 2013: 88 · 2012: 88
- FWCI
- 30.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- National Institutes of Health (n01mh070009-000, n01mh070001-008, n01mh070010-001, n01mh080011-005)
- National Institute of Mental Health (N01-MH-80011, N01 MH 70010, K23MH001883, N01 MH-70001, N01 MH 70009)
- National Center for Research Resources (M01-RR 00750, M01 RR-00052, M01-RR-00034, M01RR000750, M01RR000052, M01RR000034)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- risperidone, autism spectrum disorder, atypical antipsychotics, irritability, tantrums, aggression, self-harm, Aberrant Behavior Checklist, weight gain, adverse effects, children
- MeSH terms
- Adolescent, Autistic Disorder, Child, Child Behavior, Child, Preschool, Double-Blind Method, Female, Humans, Male, Antipsychotic Agents, Treatment Outcome, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.